KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Debt Ratio (2016 - 2025)

Sarepta Therapeutics has reported Debt Ratio over the past 16 years, most recently at 0.25 for Q4 2025.

  • For Q4 2025, Debt Ratio fell 13.75% year-over-year to 0.25; the TTM value through Dec 2025 reached 0.25, down 13.75%, while the annual FY2025 figure was 0.25, 13.75% down from the prior year.
  • Debt Ratio for Q4 2025 was 0.25 at Sarepta Therapeutics, down from 0.31 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.49 in Q4 2022 and troughed at 0.25 in Q4 2025.
  • A 5-year average of 0.37 and a median of 0.37 in 2023 define the central range for Debt Ratio.
  • Biggest five-year swings in Debt Ratio: skyrocketed 69.05% in 2021 and later decreased 24.34% in 2024.
  • Year by year, Debt Ratio stood at 0.35 in 2021, then surged by 41.67% to 0.49 in 2022, then fell by 23.18% to 0.38 in 2023, then decreased by 24.34% to 0.29 in 2024, then fell by 13.75% to 0.25 in 2025.
  • Business Quant data shows Debt Ratio for SRPT at 0.25 in Q4 2025, 0.31 in Q3 2025, and 0.31 in Q2 2025.